WO2007130725A2 - Use of hmgb1 for protection against ischemia reperfusion injury - Google Patents

Use of hmgb1 for protection against ischemia reperfusion injury Download PDF

Info

Publication number
WO2007130725A2
WO2007130725A2 PCT/US2007/061709 US2007061709W WO2007130725A2 WO 2007130725 A2 WO2007130725 A2 WO 2007130725A2 US 2007061709 W US2007061709 W US 2007061709W WO 2007130725 A2 WO2007130725 A2 WO 2007130725A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
organ
tissue
administered
injury
Prior art date
Application number
PCT/US2007/061709
Other languages
French (fr)
Other versions
WO2007130725A3 (en
Inventor
Allan Tsung
Timothy R. Billiar
Mitchell P. Fink
Kevin J. Tracey
Original Assignee
University Of Pittsburgh Of The Commonwealth System Of Higher Education
The Feinstein Institute For Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pittsburgh Of The Commonwealth System Of Higher Education, The Feinstein Institute For Medical Research filed Critical University Of Pittsburgh Of The Commonwealth System Of Higher Education
Publication of WO2007130725A2 publication Critical patent/WO2007130725A2/en
Publication of WO2007130725A3 publication Critical patent/WO2007130725A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Inflammation is the reaction of living tissue to injury. During inflammation, a complex of cytologic and chemical reactions of affected blood vessels and adjacent tissues respond to an injury or abnormal stimulation caused by a physical, chemical or biological agent. Signaling agents are released, attracting tissue macrophages and white blood cells. Proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-I) are activated, giving rise to inflammation.
  • TNF tumor necrosis factor
  • IL-I interleukin-1
  • TNF and IL-I are mediators of septic shock and associated cardiopulmonary dysfunction, acute respiratory distress syndrome (ARDS) and multiple organ failure.
  • ARDS acute respiratory distress syndrome
  • Ischemic injury or injury following ischemia, includes cellular damage resulting from an ischemic insult, which can occur upon the restriction or cessation of the flow of oxygen to an organ or tissue, such as by blockage or disconnection of one or more blood vessels. Ischemia can occur gradually or rapidly and can be either warm or cold.
  • Ischemia and reperfusion (I/R) injury is a pathophysiologic process whereby hypoxic organ damage is accentuated following return of blood flow and oxygen delivery following ischemia.
  • the pathophysiology of ischemia and reperfusion injury includes both direct cellular damage as the result of the ischemic insult as well as delayed dysfunction and damage resulting from activation of inflammatory pathways.
  • An event of ischemia can be controlled or uncontrolled.
  • Controlled events can occur in vivo, ex vivo, or in vitro, during therapeutic treatment, such as a surgical procedure, during organ transplantation, during investigatory research, or in any circumstance under which they are deliberately induced.
  • Most common controlled events include surgical procedures such as vascular surgery and cardiac bypass, as well as organ transplantation.
  • Uncontrolled events can arise gradually, such as by accumulation of plaque in a coronary artery, or rapidly, such as during acute illness or upon injury. Ischemia and reperfusion can be controlled or uncontrolled independently.
  • uncontrolled ischemia can be treated with controlled reperfusion, such as in revascularization of a myocardial infarct, or in resuscitative treatment of hemorrhagic and/or hypovolemic shock.
  • controlled reperfusion such as in revascularization of a myocardial infarct, or in resuscitative treatment of hemorrhagic and/or hypovolemic shock.
  • transient episodes of ischemia followed by reperfusion are encountered during controlled procedures such as solid organ transplantation or elective liver resection, when inflow occlusion or total vascular exclusion can be used to minimize blood loss.
  • Inflammatory injury due to trauma, ischemia, and/or reperfusion are associated with, for example, anaphylaxis, apoptosis, burn injury, bursitis, cardiopulmonary bypass surgery, cerebral infarction, circulatory shock, compartment syndrome, congestive heart failure, conjunctivitis, coronary angioplasty blood vessel attachment, coronary artery obstruction, crushing injury, dermatitis, diseases involving angiogenesis, frostbite, graft rejection, gram negative bacteria-mediated circulatory shock, gram positive bacteria- mediated circulatory shock, hemodynamic shock, hemorrhage, hemorrhagic shock, hyperoxic alveolar injury, hypersensitivity, kidney failure, limb attachment or reattachment, liver failure, mycobacterial infection, myocardial infarction, myocardial ischemia, nephrotic syndrome, organ attachment or reattachment, organ reperfusion, periarteritis nodosa, radiation damage, septic shock, solid organ transplantation, spinal/
  • Methods of treating and preventing inflammation are known in the art, including administration of pharmaceuticals such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDS), COX-2 inhibitors, or cytotoxic agents.
  • An inhibitor of TNF production, HU-211 was shown to improve the outcome of closed brain injury in an experimental model (Shohami, et al, J Neuroimmunol. 72:169 (1997)).
  • an IL-I receptor antagonist was shown to inhibit fatty streak formation associated with atherosclerosis, a disease known to have an inflammatory component (EIhage et al. ; Circulation, 97:242 (1998)).
  • U.S. Pat. No. 6,811,768 to Zapol, et al. describes the use of inhaled nitric oxide (NO) to decrease injury in pulmonary ischemia and reperfusion.
  • NO inhaled nitric oxide
  • Preconditioning is another strategy for protection that has been studied extensively in many models of organ injury. By pre-exposing the organ to a minor stress at a predetermined time point, preconditioning renders the organ less vulnerable to a subsequent injury.
  • stimuli such as heat (Ishikawa, et al., J. Surg. Res. 97:178-184 (1999)), endotoxins including lipopolysaccharides (LPS) (Colleiti, et al., J. Surg. Res. 57:337-343 (1994)), ischemia (Cavalieri, et al., Liver Transpl.
  • Preconditioning has also been undertaken using pharmacologic agents such as adenosine, IL-IO, S-adenosyl-L-methionine, and cromakalim. See, e.g., Tsai, et al., Shock 21(3):195-209 (2004).
  • the invention provides a method of protecting an organ or tissue from injury comprising administering administration of a High Mobility Group Box 1 (HMGBl) protein to the organ or tissue, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
  • HMGBl High Mobility Group Box 1
  • the invention provides a method of protecting an organ or tissue from ischemic injury comprising administering administration of an HMGBl protein to the organ or tissue, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
  • the invention provides a method of protecting an organ or tissue from injury resulting from ischemia and reperfusion comprising administration of an
  • HMGBl protein to the organ or tissue prior to completion of reperfusion, wherein the
  • HMGBl protein is administered in an amount effective to protect the organ or tissue from injury.
  • the invention also provides a method of protecting an organ or tissue from traumatic injury comprising administration of an HMGBl protein to the organ or tissue, wherein the HMGBl protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
  • the invention also provides a method of preparing an organ or tissue for transplantation from a donor into a recipient comprising administration of an HMGB 1 protein to the donor, wherein the organ or tissue is within the donor.
  • the invention provides a method of preparing an organ or tissue for implantation into a recipient comprising administration of an HMGBl protein to the organ or tissue ex vivo.
  • the invention provides a composition for the prevention of injury to an organ following ischemia and reperfusion, comprising an HMGBl protein and a pharmaceutically acceptable carrier.
  • the invention also provides a kit comprising a composition for the prevention of injury to an organ following ischemia and reperfusion and suitable instructions for administration, and optionally comprising a means for administration of the composition, wherein the composition comprises an HMGBl protein and a pharmaceutically acceptable carrier.
  • the invention provides for use of an HMGB 1 protein in preparation of a medicament for use in protecting an organ from injury caused by an event selected from the group consisting of ischemia, reperfusion, and trauma.
  • Figures IA-C show effects of HMGB 1 pretreatment on serum alanine aminotransferase (ALT) levels, serum TNF and IL-6 levels, and NF- ⁇ B activation.
  • Figure IA depicts serum ALT levels for mice pretreated with rHMGBl (2, 5, or 20 ⁇ g) or vehicle PBS i.v. one hour prior to ischemia, then subjected to ischemia and six hours of reperfusion.
  • Figure IB depicts serum TNF and IL-6 levels for mice pretreated with 20 ⁇ g HMGBl or vehicle, then subjected to ischemia and six hours of reperfusion.
  • Data in Figures IA and IB reflect means ⁇ SE, n - six mice per group.
  • Figure 1C depicts NF- ⁇ B activation during hepatic I/R injury for mice pretreated with rHMGBl or vehicle PBS before undergoing ischemia and one hour of reperfusion. Assay shown is representative of three experiments with similar results.
  • Figures 2A-B show effects of HMGBl pretreatment on TLR signaling regulators.
  • Figure 2A depicts expression of IRAK-M and phosphorylated IRAK-I in mice pretreated with 20 ⁇ g rHMGBl or vehicle PBS at various time points, along with a ⁇ -actin control. Each lane provides results for a single animal. Blot shown is representative of three experiments with similar results.
  • Figure 2B shows levels of IRAK-M in mice treated with 20 ⁇ g rHMGBl or vehicle PBS at several time points.
  • Figures 3A-B show effects of HMGBl pretreatment on wild type mice as compared to TLR4-mutant mice.
  • Figure 3(A) depicts serum ALT levels for TLR4-mutant mice (C3H/HeJ) and their wild-type mice counterpart (C3H/HeOuj), pretreated with 20 ⁇ g rHMGBl or vehicle PBS one hour prior to ischemia.
  • Figure 3B depicts serum TNF and IL-6 levels for TLR4-mutant mice and their wild-type counterparts, pretreated with 20 ⁇ g HMGBl or vehicle PBS, then subjected to ischemia and six hours of reperfusion.
  • Figure 4 depicts IRAK-M levels at 1 and 6 hours after reperfusion in TLR4- mutant mice as compared to wild type mice, with all mice pretreated with 20 ⁇ g rHMGBl or vehicle PBS one hour prior to ischemia. Each lane provides results for a separate animal, Blot shown is representative of three experiments with similar results.
  • an "HMGBl protein” is any polypeptide having the sequence of a vertebrate HMGBl protein, or a polypeptide having a related sequence (such as HMGB2), as well as variant, analog, homolog, and fragments thereof that have sufficient activity to be suitably employed to protect injury as discussed herein.
  • the HMGB 1 protein is a polypeptide having the sequence of a mammalian HMGBl protein such as GenBank Accession Number AAA40729 (SEQ ID NO:2) .
  • the HMGBl protein can have the sequence of human HMGBl, such as GenBank Accession Number AAV38961 or CAG33144.
  • the HMGBl protein can have a sequence as disclosed in GenBank Accession Numbers AAB08987 (human), AAH88402 (rat), P07155 (rat), AAA20508 (mouse), AAP36330 (human synthetic), AAC27651 (spalax ehrenbergi), XP516325 (chimpanzee), AAI02930 (bos taurus), AAA31050 (sus scrofa), XP484795 (mouse), CAA76978 (gallus gallus), AAH63332 (xenopus tropicalis), AAA64970, S29857, P09429, or NP_002119, the entire teachings of which are incorporated herein by reference.
  • HMGBl is highly conserved among species.
  • proteins related to HMGBl that can be employed as the HMBGl protein in the context of the present invention include, but are not limited to mammalian HMGB2, HMG-2A, HMGl 4, HMGl 7, HMG I and HMGY; nonmammalian HMG Tl and HMG T2 (rainbow trout), HMG-X (Xenopus), HMG D/Z (Drosophila), yeast polypeptides NHPlO protein (HMG protein homolog NHP 1) and non-histone chromosomal protein; HMG 1/2 like protein (wheat, maize, soybean); upstream binding factor (UBF-I) 5 single-strand recognition protein (SSRP) or structure-specific recognition protein; the HMG homolog TDP-I; mammalian sex-determining region Y protein (SRY, testis-determining factor); fungal proteins: mat-1 , ste 11 and Mc 1; SOX 14 (as well as SOX 14 (as well as SO
  • An HMGBl protein can also be or comprise a biologically-active variant, analog, homolog, or derivative of full length, wild-type (i.e., native) HMGBl and proteins related to HMGBl (including the examples disclosed herein) or fragment thereof.
  • biologically active it is meant that a variant, analog, homolog, or derivative of native HMGBl and proteins related to HMGB lor fragment thereof possesses sufficient activity to be suitably employed to protect injury as discussed herein.
  • HMGBl variants are polypeptides that retain at least one biological activity of native HMGBl or proteins related to HMGBl but differ in amino acid sequence.
  • a variant can be substantially identical to a native protein as described above.
  • a sequence can also be a variant if the DNA encoding the sequence is capable of hybridizing under stringent conditions to the complement of DNA encoding a native HMGB 1 protein.
  • Stringent conditions are conditions under which a first nucleic acid sequence (e.g., probe) will hybridize to a second nucleic acid sequence (e.g., target), such as in a complex mixture of nucleic acids.
  • Stringent conditions are sequence-dependent and will be different in different circumstances.
  • Stringent conditions can be selected to be about 5-1O 0 C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength pH.
  • the T m can be the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T m , 50% of the probes are occupied at equilibrium).
  • Stringent conditions can be those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 0 C for short probes (e.g., about 10-50 nucleotides) and at least about 60°C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal can be at least 2 to 10 times background hybridization.
  • Exemplary stringent hybridization conditions include the following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65 0 C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.
  • IJ HMGBl homologs are polypeptides native to different species that retain biological activity (e.g., human and porcine insulin, human and salmon calcitonin, etc.) or intraspecies isomers of a polypeptide (protein "families" such as the cytochrome P450 family).
  • proteins "families" such as the cytochrome P450 family
  • HMGBl analogs are polypeptides that differ in amino acid sequence from native HMGB 1 but retain at least one biological activity of a native HMGB 1 protein, as described above. These analogs can differ in amino acid sequence from HMGBl 5 e.g., by the insertion, or substitution of amino acids. Preferably, a substitution is conservative, A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. MoI.
  • the hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge, and include the following values: alanine (+1.8), arginme (-4.5), asparagine (-3.5), aspartate (-3.5), cysteine/cystine (+2.5), glycine (-0,4), glutamate (-3.5), glutamine (-3.5), histidine (-3.2), isoleucine (+4.5), leucine (+3.8), lysine (-3.9), methionine (+1.9), phenylalanine (+2.8), proline (-1.6), serine (-0.8), threonine (-0.7), tryptophan (-0.9), tyrosine (-1.3), and valine (+4.2).
  • hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function.
  • a consideration of the hydrophilicity of amino acids in the context of a polypeptide permits calculation of the greatest local average hydrophilicity of that polypeptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity.
  • U.S. Pat. No. 4,554,101 incorporated herein by reference.
  • Hydrophilicity values for each of the common amino acids as reported in U.S. Pat. No.
  • 4,554,101 are: alanine (-0.5), arginine (+3.0), asparagine (+0.2), aspartate (+3.0 .+-.1), cysteine (-1.0), glycine (0), glutamate (+3.0.+-.1), glutamine (+0.2), histidine (-0.5), isoleucine (-1.8), leucine (-1.8), lysine (+3.0), methionine (-1,3), phenylalanine (-2.5), proline (-0.5.+-.1), serine (+0.3), threonine (-0.4), tryptophan (-3.4), tyrosine (-2.3), and valine (-1.5).
  • substitutions can result in proteins retaining biological activity, for example immunogenicity, as is understood in the art.
  • substitutions are performed with amino acids having hydrophilicity values within +/-2 of each other.
  • Both the hyrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicily, hydrophilicity, charge, size, and other properties.
  • HMGBl derivatives are proteins or peptides that differ from native HMGBl in ways other than primary structure (i.e., amino acid sequence).
  • ECM signaling molecule derivatives can differ from native HMGB 1 by being glycosylated, one form of post-translational modification.
  • polypeptides can exhibit glycosylation patterns due to expression in heterologous systems.
  • the various polypeptides of the present invention, as described above, can be provided as discrete polypeptides or be linked, e.g., by covalent bonds, to other compounds.
  • other HMGBl derivatives include, but are not limited to, fusion proteins having a covalently modified N or C-terminus, PEGylated polypeptides, polypeptides associated with lipid moieties, alkylated polypeptides, polypeptides linked via an amino acid side-chain functional group to other polypeptides or chemicals, and additional modifications as would be understood in the art.
  • these polypeptides retain at least one biological activity of a native HMGB 1 protein, then these polypeptides are HMGBl derivatives in the context of the invention, and if they also have sufficient activity to be suitably employed to protect injury as discussed herein, then such HMGBl derivatives also are HMGBl proteins.
  • a variant, analog, homolog, or derivative of a native HMGB 1 or protein related to HMGBl has at least 60%, or more preferably, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% similarity to the native sequence. More preferably, a variant, analog, homolog, or derivative of a native HMGBl or protein related to HMGBl has at least 60%, or more preferably, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the native sequence.
  • a sequence is substantially identical if it is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical over a region of 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40 > 45, 50 s 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids.
  • Sequence identity and/or similarity can be determined using standard BLAST parameters or any other measure of sequence identity and/or similarity as known to one of ordinary skill in the art.
  • the percentage can be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity.
  • the residues of single sequence are included in the denominator but not the numerator of the calculation.
  • Fragments of HMGBl a protein related to HMGB 1 , or of a variant, analog, or honiolog thereof that retain one or more activities of native HMGBl, and which have sufficient activity to protect injury as discussed herein, also are suitable HMGBl proteins for use in the context of the present invention.
  • Biologically active fragments of HMGBl can be naturally occurring or non-naturally occurring, including recombinant fragments of a HMGBl or a protein related to HMGBl. Due to the high level of conservation of HMGBl proteins, it will be expected that one skilled in the art will identify biologically active sequences from the various proteins disclosed above based on the identification of the regions corresponding to the A box and B box.
  • a fragment for use in the present invention comprises a sequence of at least 5, such as at least 10, and more preferably at least 15 or at least 20, such as at least 30 or a least 50 contiguous amino acids of a native HMGB 1 , a protein related to HMGB 1 , or of a variant, analog, or homolog thereof.
  • a fragment can include a sequence of substantially all of the native HMGBl, a protein related to HMGBl, or of a variant, analog, or homolog thereof or it can comprise less than substantially all of native HMGBl, a protein related to HMGBl, or of a variant, analog, or homolog thereof.
  • a fragment can comprise a sequence of up to about 150, such as up to about 125 or up to about 100, or up to about 75 contiguous amino acids of a native HMGBl, a protein related to HMGBl, or of a variant, analog, or homolog thereof.
  • Exemplary fragments include polypeptides corresponding to the portion of HMGBl designated the "A box” as well as the portion of HMGBl designated the "B box.” Sequences of A box fragments can correspond approximately to amino acids 4-89 of a full length HMGBl protein, and sequences of B box fragments can correspond approximately to amino acids 90-174, as described in Bianchi, et al > EMBO J. 11(3): 1055-1063 (1992).
  • Fragments can comprise all or a portion of the A box, all or a portion of the B box or comprise portions of both the A box and the B box. Fragments can comprise one or more of the sequences disclosed at SEQ ID NO:25-2 ⁇ . Preferably, fragments comprise the B box or a portion of the B box such as SEQ ID NO:26. Fragments can also comprise amino acids 1-20 of the B box region of any HMGBl protein.
  • HMGB 1 is a nuclear protein involved in transcriptional activation and DNA folding.
  • extracellular HMGBl has been shown to be a critical mediator of the innate immune response to infection and injury, itself having cytokine properties.
  • HMGBl has been shown to be a late mediator in the inflammatory response, induced by early proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-I. Wang, et al., Science, 285:248-251 (1999). Additionally, HMGBl can also play a role as an early mediator following acute, local organ injury. Tsung, et al., J. Exp. Med. 201(7): 1135- 1143 (2005).
  • TNF tumor necrosis factor
  • HMGB 1 Despite its cellular ubiquity, the presence of serum (extracellular) HMGB 1 indicates injury. Serum levels of HMGBl are undetectable in normal human patients. Tracey, et al., WO 00/47104. Elevated levels of HMGBl can occur in conjunction with sepsis, a condition associated with activation of pro-inflammatory cytokines, as well as hemorrhagic shock. Andersson, et al., J. Exp. Med. 192(4):565-570 (2000). Elevated HMGBl levels have also been associated with injury following ischemia and reperfusion (IfR). Tsung, et al., J. Exp. Med. 201(7): 1135-1145 (2005). The most dramatically elevated HMGBl levels can be associated with lethality.
  • IfR ischemia and reperfusion
  • HMGBl Previous attempts to decrease or inhibit HMGBl have included administration of antibodies of HMGB 1 as well as administration of certain fragments of HMGB 1.
  • U.S. Pat. Pub. 2003/0060410 by Tracey, et al. describes the use of certain HMGBl fragments, specifically A box fragments, as inhibitory polypeptides and the use of antibodies to decrease HMGBl levels in a sepsis model.
  • HMGBl antibodies, inhibitory HMGBl fragments and analogs, as well as four-way DNA have been suggested as possible antagonists and/or inhibitors for HMGBl.
  • the invention provides a method of protecting an organ or tissue from injury caused by ischemic insults, reperfusion following ischemia, and trauma. These events can be either controlled or uncontrolled, as noted above.
  • the HMGBl protein can be administered to any organ or tissue in need thereof at the discretion of one skilled in the art.
  • the organ or tissue is selected from the group consisting of a brain, a heart, a liver, a portion of a liver, a lung, a portion of a lung, a kidney, an intestine, a portion of an intestine, a pancreas, an eye, a muscle, a portion of a muscle, a bone, a portion of a bone, a nerve tissue, a vascular tissue, or an epithelial tissue.
  • the organ or tissue is a heart, a brain, a liver or a portion of a liver, or a bone or a portion of a bone.
  • the organ or tissue can be in a host (in vivo), or in vitro.
  • the method can have veterinary or research applications, but preferably it is employed in the medical context, in which instance the host (and the organ or tissue) preferably is human.
  • the host in veterinary or research applications, and also in the context of xenotransplantation into a human recipient, the host can be a non-human animal (such as a mouse, rat, rabbit, cow, pig, chimpanzee, cat, or dog).
  • a method for protecting an organ or tissue from ischemic injury comprising administration of an HMGBl protein to the organ or tissue, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
  • Conditions associated with uncontrolled ischemia include stroke and certain cardiac disorders, such as myocardial infarct. Uncontrolled ischemia can also occur during acute occlusion of blood supply to organs or limbs.
  • the inventive method can comprise administering the HMGBl protein to the affected area (e.g., brain or region of the brain) within a brief time following the stroke.
  • the inventive method comprises administering the HMBGl to the affected area of the heart shortly after ischemia.
  • a method for protecting an organ or tissue from injury resulting from ischemia and reperfusion comprising administration of an HMGBl protein to the organ or tissue prior to completion of reperfusion, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury.
  • the methods of the present invention can preferably be employed in any medically appropriate circumstance that results in or that can result in injury due to ischemia and/or reperfusion, such as can occur when the ischemia and reperfusion occur during a surgical procedure or during organ transplantation.
  • Examples of conditions or procedures generating a risk of injury attributable to reperfusion following ischemia include liver resection; revascularization following myocardial infarction, such as by thrombolytic therapy, stenting, or surgical repair; revascularization following stroke, such as by thrombolytic therapy or surgical repair; or revascularization following vascular injury including repair or reattachment of a limb following ischemic injury or surgical repair of an aneurysm.
  • Organ transplantation is a preferred application of the inventive method.
  • the method involves harvesting an organ from a donor (involving ischemia) and transplanting the organ into a recipient (involving reperfusion).
  • the donor can be a living donor (e.g., of a kidney, skin graft, or other organ) or a cadaver donor. If the donor is a cadaver donor, the donor can be a heart-beating or a non-heart-beating cadaver donor.
  • the donor (and the organ) can be of any desired species, typically mammalian, but most preferably is allospecif ⁇ c to the recipient. However, the method can be employed in the xenotransplantation context, in which case the donor (and organ) are of a different species than the recipient.
  • the HMGBl protein can be administered to the organ prior to harvest or post harvest,
  • the HMGBl protein can be administered to the recipient prior to or after the organ has been implanted (e.g., prior to reperfusion or during reperfusion of the organ), such that the HMGBl protein permeates a portion of the vasculature of the organ.
  • the HMGBl protein can be administered to the donor (e.g., systemically or locally to the organ in question) prior to ischemia such that it permeates a portion of the vasculature of the organ to be harvested.
  • the inventive method can be used to prepare the organ or tissue for transplantation from the donor into the recipient.
  • the method also can be employed to prepare an organ or tissue for implantation into a recipient by administering the HMGBl protein to the organ or tissue ex vivo (i.e., after it has been harvested from the donor but before implantation into the recipient).
  • the organ can be perfused with a composition comprising the HMGBl protein for a period of time ex vivo.
  • a method for protecting an organ or tissue from traumatic injury.
  • the method comprises administration of an HMGBl protein to the organ or tissue, wherein the HMGBl protein in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
  • Traumatic injury that can be treated in accordance with the inventive method can include, for example, bone fractures, burns, lacerations, blunt trauma, blast injuries, traumatic amputations, crushing injuries, traumatic hematoma or aneurysm, as well as other injuries known to one skilled in the art. Additionally, traumatic injury includes damage to organs or tissue that can occur during surgical procedures, regardless of whether ischemia and/or reperfusion occurs.
  • the HMGBl protein can be administered before, during, or after the trauma or ischemia, provided that it is administered in sufficient time to achieve its protective effect.
  • the HMGBl protein is administered prior to about one hour after trauma or ischemia.
  • the HMGBl protein can be administered prior to about 45, 30, 15, 10, or 5 minutes after injury. If the event leading to injury includes reperfusion, the HMGBl protein is most preferably administered before reperfusion is completed. If an event leading to trauma or ischemia is controlled, the HMGBl protein is preferably administered prior to the trauma or ischemia.
  • the HMGBl protein can be administered about 5, 10, 15, 30, or 45 minutes prior to trauma or ischemia.
  • the HMGBl protein is administered about one hour prior to the trauma or ischemia. In some cases, it can be advantageous to administer the HMGB 1 protein more than about one hour prior to the trauma or ischemia.
  • the HMGBl protein can be administered in a dosage of about 5 ⁇ g to about 35 mg, or greater than about 35 mg.
  • the dosage can be about 5 ⁇ g to about 20 ⁇ g, about 20 ⁇ g to about 1 mg, or about 1 mg to about 10 mg.
  • the dosage is preferably about 10 mg to about 35 mg.
  • the dosage can be greater than 35 mg.
  • One skilled in the art can readily select a correct dosage based on the circumstances of treatment.
  • the organ or tissue is located in the host (which, in the context of transplantation, can be a donor or a recipient)
  • the HMGBl protein can be administered systemically to the host.
  • the HMGB 1 protein can be administered by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, topical, transmucosal, oral., or by another route known to one skilled in the art.
  • the HMGBl protein is formulated for administration by injection. It is particularly preferred to formulate the HMGBl protein for rapid delivery by methods known to one skilled in the art.
  • the HMGBl protein can be administered locally to the organ or tissue.
  • the HMGBl protein can be administered by injection, catheter infusion, surface application, immersion in a bath, or by other means known to one skilled in the art.
  • HMGB 1 can be administered directly to a heart during treatment for myocardial infract by injection to a blood vessel in combination with angioplasty, or by application of a medicated stent.
  • the invention further provides a composition comprising an HMGBl protein for the prevention of injury to an organ or tissue due to ischemia, reperfusion, or trauma.
  • the invention pertains to the use of an HMGBl protein in preparation of a medicament for use in protecting an organ or tissue from injury caused by an event selected from the group consisting of ischemia, reperfusion, and trauma.
  • the composition comprises an HMGB 1 protein and a pharmaceutically acceptable carrier.
  • the composition can be formulated for administration by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, topical, or oral.
  • compositions suitable for local or systemic injectable administration include aqueous and nonaqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and nonaqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
  • sterile liquid carrier for example, water
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, or tablets.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • solutions for injection are free of endotoxin.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methy ⁇ methacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • macroemulsions for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • liposomes containing the HMGBl protein can be prepared by such methods as described in Epstein el al., Proc. Natl. Acad. Sci.
  • Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.
  • Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG- derivatized phosphatidylelhanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Polypeptides of the present invention can be conjugated to the liposomes as described in Martin et al. > J. Biol. Chem., 257:286-288 (1982) via a disulfide interchange reaction.
  • Administration into the airways can provide either systemic or local administration, for example to the trachea and/or the lungs. Such administration can be made via inhalation or via physical application, using aerosols, solutions, and devices such as a bronchoscope.
  • compositions herein are conveniently delivered from an insufflator, a nebulizer, a pump, a pressurized pack, or other convenient means of delivering an aerosol, non-aerosol spray of a powder, or noon-aerosol spray of a liquid.
  • Pressurized packs can comprise a suitable propellant such a liquefied gas or a compressed gas.
  • Liquefied gases include, for example, fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, hydrochlorocarbons, hydrocarbons, and hydrocarbon ethers.
  • Compressed gases include, for example, nitrogen, nitrous oxide, and carbon dioxide.
  • the dosage unit can be determined by providing a valve to deliver a controlled amount.
  • the powder mix can include a suitable powder base such as lactose or starch.
  • the powder composition can be presented in unit dosage form such as, for example, capsules, cartridges, or blister packs from which the powder can be administered with the aid of an inhalator or insufflator.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays, inhaled aerosols, suppositories, mouthwashes, rapidly dissolving tablets, or lozenges.
  • the active compounds are formulated into ointments, salves, gels, foams, or creams as generally known in the art.
  • the pharmaceutical compositions can be delivered using drug delivery systems.
  • drug delivery systems include hyaluronic acid solutions or suspensions of collagen fragments.
  • the drugs can be formulated in microcapsules, designed with appropriate polymeric materials for controlled release, such as polylactic acid, ethylhydroxycellulose, polycaprolactone, poly capro lactone diol, polylysine, polyglycolic, polymaleic acid, poly [N- (2-hydroxypropyl)methylacrylamide] and the like.
  • Particular formulations using drug delivery systems can be in the form of liquid suspensions, ointments, complexes to a bandage, collagen shield or the like.
  • the invention provides a kit comprising a the inventive composition and suitable instructions for administration.
  • the kit can and optionally comprise a means for administration of the composition, such as, for example, a needle, catheter, cannula, pump, transdermal patch, nebulizer, or other delivery means suitable to the mode of administration.
  • the kit facilitates ready administration of the composition or practice of the inventive method and can be deployed for use in emergency settings.
  • mice Male wild-type (C57BL/6; C3H/HeOuj) and TLR4-defective (C3H/HeJ) mice (8- 12 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). All animals were maintained in a laminar-flow, specific pathogen-free atmosphere at the University of Pittsburgh. Animal protocols were approved by the Animal Care and Use committee of the University of Pittsburgh and the experiments were performed in adherence to the National Institutes of Health Guidelines for the use of Laboratory Animals. [0070] Mice received either recombinant HMGBl or vehicle PBS intravenously at various concentrations one hour prior to ischemia.
  • HMGB 1 Recombinant HMGB 1 was prepared as described in Yang, et al., Proc Natl Acad Sci USA 101:296-301 (2004).
  • the HMGBl used for these studies contained undetectable amounts of LPS as measured by the chromogenic Limulus amoebocyte lysate assay (Associates of Cape Cod or BioWhittaker).
  • a non-lethal model of segmental (70%) hepatic warm ischemia was used as described in Tsung, et a ⁇ ., JExp Med 201 :1135-43 (2005).
  • NF- ⁇ B a transcription factor involved in signal transduction of a variety of extracellular stress stimuli such as proinflammatory and protective responses in the liver
  • nuclear extracts were prepared from the ischemic livers and subjected to electrophoretic mobility shift assay (EMSA) as described in Tsung, et al., J. Exp, Med. 201: 1135-43 (2005).
  • NF- ⁇ B DNA binding increased in the ischemic liver one hour after reperfusion in control mice when compared to sham-treated animals (Figure 1C). Mice pretreated with HMGBl exhibited less NF- ⁇ B DNA binding activity. The specificity of the NF- ⁇ B bands were confirmed by cold competition in the presence of excess unlabeled NF- ⁇ B consensus motif.
  • IRAK-M protein expression was upregulated in the livers in both control mice and in pretreated mice.
  • Western blot analysis for IRAK-M and phosphorylated IRAK-I was performed for hepatic protein lysates of the ischemic lobes at the time points shown ( Figure 2A).
  • Mice pretreated with HMGBl exhibited higher hepatic IRAK-M levels after reperfusion than control mice ( Figures 2 A-B).
  • control mice exhibited increased levels of phosphorylated IRAK-I after reperfusion .
  • mice pretreated with HMGBl phosphorylated IRAK-I levels were lower than in control mice. Based on these results, lower IRAK-I phosphorylation in the livers of mice pretreated with HMGBl was associated with increased hepatic IRAK-M expression in the pretreated mice after I/R.
  • TLR4-mutant mice and wild-type control mice were subjected to liver I/R with or without HMGBl pretreatment as described in Example 1. Serum ALT levels, serum TNF and IL- ⁇ levels, and hepatic IRAK-M expression were measured.
  • TLR4 wild-type mice treated with HMGBl exhibited decreased circulating TNF and IL-6 levels compared to control I/R animals, but TLR4-mutant mice treated with HMGBl showed no difference in levels of these cytokines when compared to mutant mice not receiving HMGBl ( Figure 3B).
  • Preconditioning during I/R can be triggered by diverse stimuli, including endotoxemia.
  • mice were treated with varying doses of LPS and subjected to liver I/R.
  • LPS from E. coli 0111 :B4 was obtained from Sigma (St. Louis, MO).
  • mice pretreated with either 5 ng or 5 ⁇ g of LPS did not exhibit a reduction in I/R-induced damage compared to control animals ( Figure 5).
  • HMGB 1 in treating myocardial infarction.
  • a patient who has suffered myocardial infarction is administered 15 mg HMGB 1 intravenously within 30 minutes after infarction.
  • Conventional treatments for myocardial infarction are also administered, including surgical repair, drug therapy, and/or insertion of a stent.
  • a patient who is being prepared for a surgical procedure bearing a risk of myocardial infarction is administered 15 mg HMGB 1 intravenously one hour prior to surgery. If myocardial infarction occurs during surgery, conventional treatments are administered. [0087] The injury to the treated patients' hearts due to myocardial infarction is decreased compared to the injury to the heart of a control patient treated only with conventional treatments.
  • a patient who has suffered an ischemic stroke is administered 15 mg HMGB 1 intravenously within 30 minutes after the stroke. Conventional treatments for ischemic stroke are also administered.
  • a patient who is being prepared for a surgical procedure bearing a risk of stroke is administered 15 mg HMGBl intravenously one hour prior to surgery. If stroke occurs during surgery, conventional treatments are administered,
  • HMGB 1 in treating traumatic injury.
  • a patient who has suffered a traumatic injury is administered 15 mg of HMGB 1 intravenously within 30 minutes after injury. Conventional treatments for the traumatic injury are also administered,
  • HMGBl in treating hemorrhagic shock.
  • a patient who is suffering from hemorrhagic shock is administered 15 mg HMGBl intravenously within 30 minutes after the insult leading to shock occurs. Conventional treatments for hemorrhagic shock are also administered.
  • a patient who is being prepared for a surgical procedure bearing a risk of extreme blood loss and/or hemorrhagic shock is administered 15 mg HMGB 1 intravenously one hour prior to surgery. If hemorrhagic shock occurs during surgery, conventional treatments are administered.
  • the patient's injury is decreased compared to a control patient treated only with conventional treatments.

Abstract

Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.

Description

USE OF HMGBl FOR PROTECTION AGAINST ISCHEMIA REPERFUSION INJURY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 60/765,545 filed February 6, 2006..
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0002] This invention was made in part with Government support under Grant Numbers R01-GM50441, R01-GM37631, R01-GM-53789, R01-GM52021, and P50-GM53789 awarded by the National Institutes of Health. The Government may have certain rights in this invention.
BACKGROUND OF THE INVENTION
[0003] Inflammation is the reaction of living tissue to injury. During inflammation, a complex of cytologic and chemical reactions of affected blood vessels and adjacent tissues respond to an injury or abnormal stimulation caused by a physical, chemical or biological agent. Signaling agents are released, attracting tissue macrophages and white blood cells. Proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-I) are activated, giving rise to inflammation.
[0004] Proinflammatory cytokines such as TNF and IL-I are mediators of septic shock and associated cardiopulmonary dysfunction, acute respiratory distress syndrome (ARDS) and multiple organ failure. In a study of patients presenting at a hospital with sepsis, a correlation was found between TNF and ΪL-6 levels and septic complications (Terregino, et al, Ann. Emerg. Med., 35:26 (2000)).
[0005] Many conditions are thought to be associated directly or indirectly with inflammatory injury, and many commonly used therapeutic methods may also result in inflammatory injury either directly or indirectly. Exemplary types of inflammatory injury include traumatic injury, ischemia, and ischemia and reper fusion. Ischemic injury, or injury following ischemia, includes cellular damage resulting from an ischemic insult, which can occur upon the restriction or cessation of the flow of oxygen to an organ or tissue, such as by blockage or disconnection of one or more blood vessels. Ischemia can occur gradually or rapidly and can be either warm or cold.
[0006] Ischemia and reperfusion (I/R) injury is a pathophysiologic process whereby hypoxic organ damage is accentuated following return of blood flow and oxygen delivery following ischemia. The pathophysiology of ischemia and reperfusion injury includes both direct cellular damage as the result of the ischemic insult as well as delayed dysfunction and damage resulting from activation of inflammatory pathways.
[0007] An event of ischemia, including ischemia with reperfusion> can be controlled or uncontrolled. Controlled events can occur in vivo, ex vivo, or in vitro, during therapeutic treatment, such as a surgical procedure, during organ transplantation, during investigatory research, or in any circumstance under which they are deliberately induced. Most common controlled events include surgical procedures such as vascular surgery and cardiac bypass, as well as organ transplantation. Uncontrolled events can arise gradually, such as by accumulation of plaque in a coronary artery, or rapidly, such as during acute illness or upon injury. Ischemia and reperfusion can be controlled or uncontrolled independently. In some cases, uncontrolled ischemia can be treated with controlled reperfusion, such as in revascularization of a myocardial infarct, or in resuscitative treatment of hemorrhagic and/or hypovolemic shock. In other cases, transient episodes of ischemia followed by reperfusion are encountered during controlled procedures such as solid organ transplantation or elective liver resection, when inflow occlusion or total vascular exclusion can be used to minimize blood loss.
[0008] Inflammatory injury due to trauma, ischemia, and/or reperfusion are associated with, for example, anaphylaxis, apoptosis, burn injury, bursitis, cardiopulmonary bypass surgery, cerebral infarction, circulatory shock, compartment syndrome, congestive heart failure, conjunctivitis, coronary angioplasty blood vessel attachment, coronary artery obstruction, crushing injury, dermatitis, diseases involving angiogenesis, frostbite, graft rejection, gram negative bacteria-mediated circulatory shock, gram positive bacteria- mediated circulatory shock, hemodynamic shock, hemorrhage, hemorrhagic shock, hyperoxic alveolar injury, hypersensitivity, kidney failure, limb attachment or reattachment, liver failure, mycobacterial infection, myocardial infarction, myocardial ischemia, nephrotic syndrome, organ attachment or reattachment, organ reperfusion, periarteritis nodosa, radiation damage, septic shock, solid organ transplantation, spinal/head trauma and concomitant severe paralysis, stroke, swelling occurring after injury, and systemic inflammatory response syndrome (SIRS).
[0009] Methods of treating and preventing inflammation are known in the art, including administration of pharmaceuticals such as corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDS), COX-2 inhibitors, or cytotoxic agents. An inhibitor of TNF production, HU-211, was shown to improve the outcome of closed brain injury in an experimental model (Shohami, et al, J Neuroimmunol. 72:169 (1997)). In an animal model, an IL-I receptor antagonist was shown to inhibit fatty streak formation associated with atherosclerosis, a disease known to have an inflammatory component (EIhage et al.; Circulation, 97:242 (1998)). U.S. Pat. No. 6,811,768 to Zapol, et al. describes the use of inhaled nitric oxide (NO) to decrease injury in pulmonary ischemia and reperfusion.
[0010) Preconditioning is another strategy for protection that has been studied extensively in many models of organ injury. By pre-exposing the organ to a minor stress at a predetermined time point, preconditioning renders the organ less vulnerable to a subsequent injury. Previous efforts to precondition organs to ischemia and reperfusion have applied stimuli such as heat (Ishikawa, et al., J. Surg. Res. 97:178-184 (1999)), endotoxins including lipopolysaccharides (LPS) (Colleiti, et al., J. Surg. Res. 57:337-343 (1994)), ischemia (Cavalieri, et al., Liver Transpl. 8:990-999 (2002)), and intermittent clamping (Murry, et al., Circulation, 74:1 124-1 136 (1986)), Preconditioning has also been undertaken using pharmacologic agents such as adenosine, IL-IO, S-adenosyl-L-methionine, and cromakalim. See, e.g., Tsai, et al., Shock 21(3):195-209 (2004).
[0011] Despite the availability of certain regimens, treatments capable of diminishing inflammatory injury, as well as methods for preventing inflammatory injury and protecting an organ or tissue from injury, are needed.
BRIEF SUMMARY OF THE INVENTION
[0012] The invention provides a method of protecting an organ or tissue from injury comprising administering administration of a High Mobility Group Box 1 (HMGBl) protein to the organ or tissue, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury. [0013] In one aspect, the invention provides a method of protecting an organ or tissue from ischemic injury comprising administering administration of an HMGBl protein to the organ or tissue, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
[0014) In another aspect, the invention provides a method of protecting an organ or tissue from injury resulting from ischemia and reperfusion comprising administration of an
HMGBl protein to the organ or tissue prior to completion of reperfusion, wherein the
HMGBl protein is administered in an amount effective to protect the organ or tissue from injury.
[0015] In a further aspect, the invention also provides a method of protecting an organ or tissue from traumatic injury comprising administration of an HMGBl protein to the organ or tissue, wherein the HMGBl protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
[0016] The invention also provides a method of preparing an organ or tissue for transplantation from a donor into a recipient comprising administration of an HMGB 1 protein to the donor, wherein the organ or tissue is within the donor.
[0017] In a related aspect, the invention provides a method of preparing an organ or tissue for implantation into a recipient comprising administration of an HMGBl protein to the organ or tissue ex vivo.
[0018] Additionally, the invention provides a composition for the prevention of injury to an organ following ischemia and reperfusion, comprising an HMGBl protein and a pharmaceutically acceptable carrier.
[0019] The invention also provides a kit comprising a composition for the prevention of injury to an organ following ischemia and reperfusion and suitable instructions for administration, and optionally comprising a means for administration of the composition, wherein the composition comprises an HMGBl protein and a pharmaceutically acceptable carrier.
[0020] Finally, the invention provides for use of an HMGB 1 protein in preparation of a medicament for use in protecting an organ from injury caused by an event selected from the group consisting of ischemia, reperfusion, and trauma. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)
[0021] Figures IA-C show effects of HMGB 1 pretreatment on serum alanine aminotransferase (ALT) levels, serum TNF and IL-6 levels, and NF-κB activation. Figure IA depicts serum ALT levels for mice pretreated with rHMGBl (2, 5, or 20 μg) or vehicle PBS i.v. one hour prior to ischemia, then subjected to ischemia and six hours of reperfusion. Figure IB depicts serum TNF and IL-6 levels for mice pretreated with 20 μg HMGBl or vehicle, then subjected to ischemia and six hours of reperfusion. Data in Figures IA and IB reflect means ± SE, n - six mice per group. *P<.05 versus mice subjected to I/R given vehicle PBS. Figure 1C depicts NF-κB activation during hepatic I/R injury for mice pretreated with rHMGBl or vehicle PBS before undergoing ischemia and one hour of reperfusion. Assay shown is representative of three experiments with similar results. [0022] Figures 2A-B show effects of HMGBl pretreatment on TLR signaling regulators. Figure 2A depicts expression of IRAK-M and phosphorylated IRAK-I in mice pretreated with 20 μg rHMGBl or vehicle PBS at various time points, along with a β-actin control. Each lane provides results for a single animal. Blot shown is representative of three experiments with similar results. Figure 2B shows levels of IRAK-M in mice treated with 20 μg rHMGBl or vehicle PBS at several time points.
[0023] Figures 3A-B show effects of HMGBl pretreatment on wild type mice as compared to TLR4-mutant mice. Figure 3(A) depicts serum ALT levels for TLR4-mutant mice (C3H/HeJ) and their wild-type mice counterpart (C3H/HeOuj), pretreated with 20 μg rHMGBl or vehicle PBS one hour prior to ischemia. Figure 3B depicts serum TNF and IL-6 levels for TLR4-mutant mice and their wild-type counterparts, pretreated with 20 μg HMGBl or vehicle PBS, then subjected to ischemia and six hours of reperfusion. Data in figures 3 A and 3B reflect means ± SE, n = seven mice per group. *P<.05 versus TLR4 wild-type mice subjected to I/R given vehicle.
[0024] Figure 4 depicts IRAK-M levels at 1 and 6 hours after reperfusion in TLR4- mutant mice as compared to wild type mice, with all mice pretreated with 20 μg rHMGBl or vehicle PBS one hour prior to ischemia. Each lane provides results for a separate animal, Blot shown is representative of three experiments with similar results. [0025] Figure 5 depicts serum ALT levels for mice pretreated with LPS (5 ng or 5 μg) or vehicle PBS i.v. one hour prior to ischemia, then subjected to ischemia and six hours of reperfusion. Serum ALT levels were analyzed as a measure of hepatocellular injury. Data reflect means ± SE, n = six mice per group. *P<05 versus mice subjected to Ϊ/R given vehicle PBS. per group. *P<05 versus mice subjected to I/R given vehicle PBS.
DETAILED DESCRIPTION OF THE INVENTION
HMGBl Proteins
[0026] The present invention relates to methods and compositions involving HMGBl proteins. In the context of the present invention, an "HMGBl protein" is any polypeptide having the sequence of a vertebrate HMGBl protein, or a polypeptide having a related sequence (such as HMGB2), as well as variant, analog, homolog, and fragments thereof that have sufficient activity to be suitably employed to protect injury as discussed herein. [0027] In one embodiment, the HMGB 1 protein is a polypeptide having the sequence of a mammalian HMGBl protein such as GenBank Accession Number AAA40729 (SEQ ID NO:2) . The HMGBl protein can have the sequence of human HMGBl, such as GenBank Accession Number AAV38961 or CAG33144. Alternatively, the HMGBl protein can have a sequence as disclosed in GenBank Accession Numbers AAB08987 (human), AAH88402 (rat), P07155 (rat), AAA20508 (mouse), AAP36330 (human synthetic), AAC27651 (spalax ehrenbergi), XP516325 (chimpanzee), AAI02930 (bos taurus), AAA31050 (sus scrofa), XP484795 (mouse), CAA76978 (gallus gallus), AAH63332 (xenopus tropicalis), AAA64970, S29857, P09429, or NP_002119, the entire teachings of which are incorporated herein by reference. It should be noted that HMGBl is highly conserved among species. [0028] Examples of proteins related to HMGBl that can be employed as the HMBGl protein in the context of the present invention include, but are not limited to mammalian HMGB2, HMG-2A, HMGl 4, HMGl 7, HMG I and HMGY; nonmammalian HMG Tl and HMG T2 (rainbow trout), HMG-X (Xenopus), HMG D/Z (Drosophila), yeast polypeptides NHPlO protein (HMG protein homolog NHP 1) and non-histone chromosomal protein; HMG 1/2 like protein (wheat, maize, soybean); upstream binding factor (UBF-I)5 single-strand recognition protein (SSRP) or structure-specific recognition protein; the HMG homolog TDP-I; mammalian sex-determining region Y protein (SRY, testis-determining factor); fungal proteins: mat-1 , ste 11 and Mc 1; SOX 14 (as well as SOX 1-3, 6, 8, 10, 12 and 21); lymphoid specific factor (LEF-I); T-cell specific transcription factor (TCF-I); and SPlOO- HMG nuclear autoantigen. [0029] An HMGBl protein can also be or comprise a biologically-active variant, analog, homolog, or derivative of full length, wild-type (i.e., native) HMGBl and proteins related to HMGBl (including the examples disclosed herein) or fragment thereof. By "biologically active" it is meant that a variant, analog, homolog, or derivative of native HMGBl and proteins related to HMGB lor fragment thereof possesses sufficient activity to be suitably employed to protect injury as discussed herein.
[0030] HMGBl variants are polypeptides that retain at least one biological activity of native HMGBl or proteins related to HMGBl but differ in amino acid sequence. A variant can be substantially identical to a native protein as described above. A sequence can also be a variant if the DNA encoding the sequence is capable of hybridizing under stringent conditions to the complement of DNA encoding a native HMGB 1 protein. Stringent conditions are conditions under which a first nucleic acid sequence (e.g., probe) will hybridize to a second nucleic acid sequence (e.g., target), such as in a complex mixture of nucleic acids. Stringent conditions are sequence-dependent and will be different in different circumstances. Stringent conditions can be selected to be about 5-1O0C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm can be the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions can be those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 300C for short probes (e.g., about 10-50 nucleotides) and at least about 60°C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal can be at least 2 to 10 times background hybridization. Exemplary stringent hybridization conditions include the following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 650C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. [003 IJ HMGBl homologs are polypeptides native to different species that retain biological activity (e.g., human and porcine insulin, human and salmon calcitonin, etc.) or intraspecies isomers of a polypeptide (protein "families" such as the cytochrome P450 family). Non-limiting examples of some HMGBl homologs are listed above. [0032] HMGBl analogs are polypeptides that differ in amino acid sequence from native HMGB 1 but retain at least one biological activity of a native HMGB 1 protein, as described above. These analogs can differ in amino acid sequence from HMGBl5 e.g., by the insertion, or substitution of amino acids. Preferably, a substitution is conservative, A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. MoI. Biol. 157:105-132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge, and include the following values: alanine (+1.8), arginme (-4.5), asparagine (-3.5), aspartate (-3.5), cysteine/cystine (+2.5), glycine (-0,4), glutamate (-3.5), glutamine (-3.5), histidine (-3.2), isoleucine (+4.5), leucine (+3.8), lysine (-3.9), methionine (+1.9), phenylalanine (+2.8), proline (-1.6), serine (-0.8), threonine (-0.7), tryptophan (-0.9), tyrosine (-1.3), and valine (+4.2). It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. Preferably, amino acids having hydropathic indexes of +/-2 are substituted. [0033] The hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a polypeptide permits calculation of the greatest local average hydrophilicity of that polypeptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. U.S. Pat. No. 4,554,101, incorporated herein by reference. Hydrophilicity values for each of the common amino acids, as reported in U.S. Pat. No. 4,554,101, are: alanine (-0.5), arginine (+3.0), asparagine (+0.2), aspartate (+3.0 .+-.1), cysteine (-1.0), glycine (0), glutamate (+3.0.+-.1), glutamine (+0.2), histidine (-0.5), isoleucine (-1.8), leucine (-1.8), lysine (+3.0), methionine (-1,3), phenylalanine (-2.5), proline (-0.5.+-.1), serine (+0.3), threonine (-0.4), tryptophan (-3.4), tyrosine (-2.3), and valine (-1.5). Substitution of amino acids having similar hydrophilicity values can result in proteins retaining biological activity, for example immunogenicity, as is understood in the art. Preferably, substitutions are performed with amino acids having hydrophilicity values within +/-2 of each other. Both the hyrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicily, hydrophilicity, charge, size, and other properties.
[0034] Additionally, computerized algorithms are available to assist in predicting amino acid sequence domains likely to be accessible to an aqueous solvent. These domains are known in the art to frequently be disposed towards the exterior of a protein, thereby potentially contributing to binding determinants, including antigenic determinants. Having the DNA sequence in hand, the preparation of such analogs is accomplished by methods well known in the art (e.g., site-directed) mutagenesis and other techniques. [0035] HMGBl derivatives are proteins or peptides that differ from native HMGBl in ways other than primary structure (i.e., amino acid sequence). By way of illustration, ECM signaling molecule derivatives can differ from native HMGB 1 by being glycosylated, one form of post-translational modification. For example, polypeptides can exhibit glycosylation patterns due to expression in heterologous systems. The various polypeptides of the present invention, as described above, can be provided as discrete polypeptides or be linked, e.g., by covalent bonds, to other compounds. Thus, other HMGBl derivatives include, but are not limited to, fusion proteins having a covalently modified N or C-terminus, PEGylated polypeptides, polypeptides associated with lipid moieties, alkylated polypeptides, polypeptides linked via an amino acid side-chain functional group to other polypeptides or chemicals, and additional modifications as would be understood in the art. If these polypeptides retain at least one biological activity of a native HMGB 1 protein, then these polypeptides are HMGBl derivatives in the context of the invention, and if they also have sufficient activity to be suitably employed to protect injury as discussed herein, then such HMGBl derivatives also are HMGBl proteins.
[0036] Preferably, a variant, analog, homolog, or derivative of a native HMGB 1 or protein related to HMGBl has at least 60%, or more preferably, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% similarity to the native sequence. More preferably, a variant, analog, homolog, or derivative of a native HMGBl or protein related to HMGBl has at least 60%, or more preferably, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the native sequence. A sequence is substantially identical if it is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical over a region of 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40> 45, 50s 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids. [0037] Sequence identity and/or similarity can be determined using standard BLAST parameters or any other measure of sequence identity and/or similarity as known to one of ordinary skill in the art. The percentage can be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation.
(0038] Fragments of HMGBl , a protein related to HMGB 1 , or of a variant, analog, or honiolog thereof that retain one or more activities of native HMGBl, and which have sufficient activity to protect injury as discussed herein, also are suitable HMGBl proteins for use in the context of the present invention. Biologically active fragments of HMGBl can be naturally occurring or non-naturally occurring, including recombinant fragments of a HMGBl or a protein related to HMGBl. Due to the high level of conservation of HMGBl proteins, it will be expected that one skilled in the art will identify biologically active sequences from the various proteins disclosed above based on the identification of the regions corresponding to the A box and B box. Preferably, a fragment for use in the present invention comprises a sequence of at least 5, such as at least 10, and more preferably at least 15 or at least 20, such as at least 30 or a least 50 contiguous amino acids of a native HMGB 1 , a protein related to HMGB 1 , or of a variant, analog, or homolog thereof. A fragment can include a sequence of substantially all of the native HMGBl, a protein related to HMGBl, or of a variant, analog, or homolog thereof or it can comprise less than substantially all of native HMGBl, a protein related to HMGBl, or of a variant, analog, or homolog thereof. Thus, for example, a fragment can comprise a sequence of up to about 150, such as up to about 125 or up to about 100, or up to about 75 contiguous amino acids of a native HMGBl, a protein related to HMGBl, or of a variant, analog, or homolog thereof. [0039] Exemplary fragments include polypeptides corresponding to the portion of HMGBl designated the "A box" as well as the portion of HMGBl designated the "B box." Sequences of A box fragments can correspond approximately to amino acids 4-89 of a full length HMGBl protein, and sequences of B box fragments can correspond approximately to amino acids 90-174, as described in Bianchi, et al> EMBO J. 11(3): 1055-1063 (1992). Fragments can comprise all or a portion of the A box, all or a portion of the B box or comprise portions of both the A box and the B box. Fragments can comprise one or more of the sequences disclosed at SEQ ID NO:25-2ό. Preferably, fragments comprise the B box or a portion of the B box such as SEQ ID NO:26. Fragments can also comprise amino acids 1-20 of the B box region of any HMGBl protein.
[0040] HMGB 1 is a nuclear protein involved in transcriptional activation and DNA folding. In addition to its nuclear role, extracellular HMGBl has been shown to be a critical mediator of the innate immune response to infection and injury, itself having cytokine properties. HMGBl has been shown to be a late mediator in the inflammatory response, induced by early proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-I. Wang, et al., Science, 285:248-251 (1999). Additionally, HMGBl can also play a role as an early mediator following acute, local organ injury. Tsung, et al., J. Exp. Med. 201(7): 1135- 1143 (2005).
[0041] Despite its cellular ubiquity, the presence of serum (extracellular) HMGB 1 indicates injury. Serum levels of HMGBl are undetectable in normal human patients. Tracey, et al., WO 00/47104. Elevated levels of HMGBl can occur in conjunction with sepsis, a condition associated with activation of pro-inflammatory cytokines, as well as hemorrhagic shock. Andersson, et al., J. Exp. Med. 192(4):565-570 (2000). Elevated HMGBl levels have also been associated with injury following ischemia and reperfusion (IfR). Tsung, et al., J. Exp. Med. 201(7): 1135-1145 (2005). The most dramatically elevated HMGBl levels can be associated with lethality.
[0042] Previous attempts to decrease or inhibit HMGBl have included administration of antibodies of HMGB 1 as well as administration of certain fragments of HMGB 1. For example, U.S. Pat. Pub. 2003/0060410 by Tracey, et al. describes the use of certain HMGBl fragments, specifically A box fragments, as inhibitory polypeptides and the use of antibodies to decrease HMGBl levels in a sepsis model. In the context of HMGBl -mediated atherosclerosis and restenosis, HMGBl antibodies, inhibitory HMGBl fragments and analogs, as well as four-way DNA have been suggested as possible antagonists and/or inhibitors for HMGBl. U.S. Pat. Pub. 2004/0136979 by Bianchi, et al. [0043] Exogenous administration of HMGBl has previously been found to be detrimental, and often lethal. Wang, el al., Science, 285:248-251 (1999). Intratracheal administration of HMGBl has been shown to cause acute lung injury and lethality. Abraham, et al., J. Immunol. 165:2950-2954 (2000). Administration of HMGBl to mice following reperfusion worsened I/R injury as compared to sham-treated and untreated control animals. Tsung, et al., J. Exp. Med. 201(7): 1135-1145 (2005). Administration of certain fragments of HMGBl, specifically B box fragments, has been shown to recapitulate the toxicity and lethality of full length HMGBl in vivo. Li, et al., MoI. Med. Jan/Feb 2003: 37- 45. Accordingly, the present inventive method involving the administration of an HMGBl protein to protect against inflammation and organ injury following events such as ischemia, reperfusion, and/or trauma is quite surprising.
The inventive method
[0044] The invention provides a method of protecting an organ or tissue from injury caused by ischemic insults, reperfusion following ischemia, and trauma. These events can be either controlled or uncontrolled, as noted above.
[0045] The HMGBl protein can be administered to any organ or tissue in need thereof at the discretion of one skilled in the art. Preferably, the organ or tissue is selected from the group consisting of a brain, a heart, a liver, a portion of a liver, a lung, a portion of a lung, a kidney, an intestine, a portion of an intestine, a pancreas, an eye, a muscle, a portion of a muscle, a bone, a portion of a bone, a nerve tissue, a vascular tissue, or an epithelial tissue. More preferably, the organ or tissue is a heart, a brain, a liver or a portion of a liver, or a bone or a portion of a bone.
[0046] Depending on the desired application of the inventive method, the organ or tissue can be in a host (in vivo), or in vitro. The method can have veterinary or research applications, but preferably it is employed in the medical context, in which instance the host (and the organ or tissue) preferably is human. However, in veterinary or research applications, and also in the context of xenotransplantation into a human recipient, the host can be a non-human animal (such as a mouse, rat, rabbit, cow, pig, chimpanzee, cat, or dog). [0047] In one embodiment of the present invention, a method is provided for protecting an organ or tissue from ischemic injury comprising administration of an HMGBl protein to the organ or tissue, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury. Conditions associated with uncontrolled ischemia include stroke and certain cardiac disorders, such as myocardial infarct. Uncontrolled ischemia can also occur during acute occlusion of blood supply to organs or limbs. Thus, for mitigating the effects of stroke, for example, the inventive method can comprise administering the HMGBl protein to the affected area (e.g., brain or region of the brain) within a brief time following the stroke. Similarly, for treatment of cardiac ischemia, the inventive method comprises administering the HMBGl to the affected area of the heart shortly after ischemia.
[0048] In another embodiment of the present invention, a method is provided for protecting an organ or tissue from injury resulting from ischemia and reperfusion comprising administration of an HMGBl protein to the organ or tissue prior to completion of reperfusion, wherein the HMGB 1 protein is administered in an amount effective to protect the organ or tissue from injury. The methods of the present invention can preferably be employed in any medically appropriate circumstance that results in or that can result in injury due to ischemia and/or reperfusion, such as can occur when the ischemia and reperfusion occur during a surgical procedure or during organ transplantation. Examples of conditions or procedures generating a risk of injury attributable to reperfusion following ischemia include liver resection; revascularization following myocardial infarction, such as by thrombolytic therapy, stenting, or surgical repair; revascularization following stroke, such as by thrombolytic therapy or surgical repair; or revascularization following vascular injury including repair or reattachment of a limb following ischemic injury or surgical repair of an aneurysm.
[0049] Organ transplantation is a preferred application of the inventive method. In this context, the method involves harvesting an organ from a donor (involving ischemia) and transplanting the organ into a recipient (involving reperfusion). The donor can be a living donor (e.g., of a kidney, skin graft, or other organ) or a cadaver donor. If the donor is a cadaver donor, the donor can be a heart-beating or a non-heart-beating cadaver donor. The donor (and the organ) can be of any desired species, typically mammalian, but most preferably is allospecifϊc to the recipient. However, the method can be employed in the xenotransplantation context, in which case the donor (and organ) are of a different species than the recipient.
[0050] When employed to prevent injury resulting from ischemia and reperfusion during transplantation of an organ from a donor or recipient, the HMGBl protein can be administered to the organ prior to harvest or post harvest, For example, the HMGBl protein can be administered to the recipient prior to or after the organ has been implanted (e.g., prior to reperfusion or during reperfusion of the organ), such that the HMGBl protein permeates a portion of the vasculature of the organ.
[0051] Alternatively, the HMGBl protein can be administered to the donor (e.g., systemically or locally to the organ in question) prior to ischemia such that it permeates a portion of the vasculature of the organ to be harvested. In this sense, the inventive method can be used to prepare the organ or tissue for transplantation from the donor into the recipient.
(0052] The method also can be employed to prepare an organ or tissue for implantation into a recipient by administering the HMGBl protein to the organ or tissue ex vivo (i.e., after it has been harvested from the donor but before implantation into the recipient). For example, the organ can be perfused with a composition comprising the HMGBl protein for a period of time ex vivo.
[0053] In another embodiment of the present invention, a method is provided for protecting an organ or tissue from traumatic injury. In accordance with this aspect of the invention, the method comprises administration of an HMGBl protein to the organ or tissue, wherein the HMGBl protein in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury. Traumatic injury that can be treated in accordance with the inventive method can include, for example, bone fractures, burns, lacerations, blunt trauma, blast injuries, traumatic amputations, crushing injuries, traumatic hematoma or aneurysm, as well as other injuries known to one skilled in the art. Additionally, traumatic injury includes damage to organs or tissue that can occur during surgical procedures, regardless of whether ischemia and/or reperfusion occurs.
Dosage and Administration
[0054] In the performance of the inventive method, the HMGBl protein can be administered before, during, or after the trauma or ischemia, provided that it is administered in sufficient time to achieve its protective effect. Preferably, the HMGBl protein is administered prior to about one hour after trauma or ischemia. The HMGBl protein can be administered prior to about 45, 30, 15, 10, or 5 minutes after injury. If the event leading to injury includes reperfusion, the HMGBl protein is most preferably administered before reperfusion is completed. If an event leading to trauma or ischemia is controlled, the HMGBl protein is preferably administered prior to the trauma or ischemia. The HMGBl protein can be administered about 5, 10, 15, 30, or 45 minutes prior to trauma or ischemia. Preferably, the HMGBl protein is administered about one hour prior to the trauma or ischemia. In some cases, it can be advantageous to administer the HMGB 1 protein more than about one hour prior to the trauma or ischemia.
[0055] In the performance of the inventive method, the HMGBl protein can be administered in a dosage of about 5 μg to about 35 mg, or greater than about 35 mg. The dosage can be about 5 μg to about 20 μg, about 20 μg to about 1 mg, or about 1 mg to about 10 mg. In some embodiments, the dosage is preferably about 10 mg to about 35 mg. In other embodiments, the dosage can be greater than 35 mg. One skilled in the art can readily select a correct dosage based on the circumstances of treatment. [0056] If the organ or tissue is located in the host (which, in the context of transplantation, can be a donor or a recipient), the HMGBl protein can be administered systemically to the host. The HMGB 1 protein can be administered by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, topical, transmucosal, oral., or by another route known to one skilled in the art. Preferably, the HMGBl protein is formulated for administration by injection. It is particularly preferred to formulate the HMGBl protein for rapid delivery by methods known to one skilled in the art. As an alternative to systemic administration, or in addition to systemic administration, the HMGBl protein can be administered locally to the organ or tissue. The HMGBl protein can be administered by injection, catheter infusion, surface application, immersion in a bath, or by other means known to one skilled in the art. For example, HMGB 1 can be administered directly to a heart during treatment for myocardial infract by injection to a blood vessel in combination with angioplasty, or by application of a medicated stent.
Composition
[0057J For use in the inventive method, the invention further provides a composition comprising an HMGBl protein for the prevention of injury to an organ or tissue due to ischemia, reperfusion, or trauma. In this sense, the invention pertains to the use of an HMGBl protein in preparation of a medicament for use in protecting an organ or tissue from injury caused by an event selected from the group consisting of ischemia, reperfusion, and trauma. The composition comprises an HMGB 1 protein and a pharmaceutically acceptable carrier. The composition can be formulated for administration by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, topical, or oral. The composition also can comprise additional components such as diluents, adjuvants, excipients, preservatives, and pH adjusting agents, and the like. [0058] Formulations suitable for local or systemic injectable administration include aqueous and nonaqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and nonaqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, or tablets.
[0059] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Preferably solutions for injection are free of endotoxin. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. [0060] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methyϊmethacylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Specifically, liposomes containing the HMGBl protein can be prepared by such methods as described in Epstein el al., Proc. Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556. [0061] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol and PEG- derivatized phosphatidylelhanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Polypeptides of the present invention can be conjugated to the liposomes as described in Martin et al.> J. Biol. Chem., 257:286-288 (1982) via a disulfide interchange reaction. [0062] Administration into the airways can provide either systemic or local administration, for example to the trachea and/or the lungs. Such administration can be made via inhalation or via physical application, using aerosols, solutions, and devices such as a bronchoscope. For inhalation, the compositions herein are conveniently delivered from an insufflator, a nebulizer, a pump, a pressurized pack, or other convenient means of delivering an aerosol, non-aerosol spray of a powder, or noon-aerosol spray of a liquid. Pressurized packs can comprise a suitable propellant such a liquefied gas or a compressed gas. Liquefied gases include, for example, fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, hydrochlorocarbons, hydrocarbons, and hydrocarbon ethers. Compressed gases include, for example, nitrogen, nitrous oxide, and carbon dioxide. In particular, the use of dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas is contemplated. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a controlled amount. In administering a dry powder composition, the powder mix can include a suitable powder base such as lactose or starch. The powder composition can be presented in unit dosage form such as, for example, capsules, cartridges, or blister packs from which the powder can be administered with the aid of an inhalator or insufflator.
[0063] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays, inhaled aerosols, suppositories, mouthwashes, rapidly dissolving tablets, or lozenges. For transdermal administration, the active compounds are formulated into ointments, salves, gels, foams, or creams as generally known in the art.
[0064] The pharmaceutical compositions can be delivered using drug delivery systems. Such delivery systems include hyaluronic acid solutions or suspensions of collagen fragments. The drugs can be formulated in microcapsules, designed with appropriate polymeric materials for controlled release, such as polylactic acid, ethylhydroxycellulose, polycaprolactone, poly capro lactone diol, polylysine, polyglycolic, polymaleic acid, poly [N- (2-hydroxypropyl)methylacrylamide] and the like. Particular formulations using drug delivery systems can be in the form of liquid suspensions, ointments, complexes to a bandage, collagen shield or the like.
[0065] In another embodiment, the invention provides a kit comprising a the inventive composition and suitable instructions for administration. The kit can and optionally comprise a means for administration of the composition, such as, for example, a needle, catheter, cannula, pump, transdermal patch, nebulizer, or other delivery means suitable to the mode of administration. The kit facilitates ready administration of the composition or practice of the inventive method and can be deployed for use in emergency settings.
[0066] While one of skill in the art is fully able to practice the instant invention upon reading the foregoing detailed description, the following examples will help elucidate some of its features. In particular, they demonstrate the effects of HMGBl pretreatment on several indicators of I/R injury including levels of serine alanine aminotransferase, cytokines IL-6 and TNF, NF-κB, and IRAK-M. They demonstrate the effect of HMGBl pretreatment on TLR4 signaling in TLR4-mutant and wild type mice. Additionally, they demonstrate that LPS does not protect against I/R injury to liver tissue. Of course, as these examples are presented for purely illustrative purposes, they should not be used to construe the scope of the invention in a limited manner, but rather should be seen as expanding upon the foregoing description of the invention as a whole.
[0067] The procedures employed in these examples, such as surgery, histopathology, and molecular analysis of proteins and polynucleotides, are familiar to those of ordinary skill in this art. As such, and in the interest of brevity, experimental details are not recited in detail.
EXAMPLE 1
[0068] This example demonstrates that HMGB 1 treatment can protect against hepatocellular injury caused by I/R,
[0069] Male wild-type (C57BL/6; C3H/HeOuj) and TLR4-defective (C3H/HeJ) mice (8- 12 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). All animals were maintained in a laminar-flow, specific pathogen-free atmosphere at the University of Pittsburgh. Animal protocols were approved by the Animal Care and Use committee of the University of Pittsburgh and the experiments were performed in adherence to the National Institutes of Health Guidelines for the use of Laboratory Animals. [0070] Mice received either recombinant HMGBl or vehicle PBS intravenously at various concentrations one hour prior to ischemia. Recombinant HMGB 1 was prepared as described in Yang, et al., Proc Natl Acad Sci USA 101:296-301 (2004). The HMGBl used for these studies contained undetectable amounts of LPS as measured by the chromogenic Limulus amoebocyte lysate assay (Associates of Cape Cod or BioWhittaker). [0071] A non-lethal model of segmental (70%) hepatic warm ischemia was used as described in Tsung, et a\., JExp Med 201 :1135-43 (2005). After induction of anesthesia, all structures in the portal triad (hepatic artery, portal vein, and bile duct) to the left and median liver lobes were occluded with a microvascular clamp (Fine Science Tools, San Francisco, CA) for 60 minutes, and reperfusion was initiated by removal of the clamp. Temperature was monitored by rectal temperature probe and was maintained at 370C by means of a warming pad and heat lamp. Animals were sacrificed at predetermined time points after reperfusion for serum and liver samples.
[0072] Sixty minutes of warm hepatic ischemia followed by 6 hours of reperfusion resulted in increased serum ALT levels, decreased cytokine levels, decreased activation of NF-κB, and increased expression of IRAK-M as compared to control mice subjected to I/R. [0073] Levels of serum ALT, an indicator of hepatocellular injury, were measured using the Opera Clinical Chemistry System (Bayer Co., Tarrytown, NY) to assess hepatic function and cellular injury following liver ischemia. Pretreatment with 5 to 20 μg of rHMGBl resulted in significant protection from hepatic injury in a dose dependent manner (Figure IA). Liver histology confirmed the sALT estimation of liver damage (data not shown). Severe sinusoidal congestion and hepatocellular necrosis was present in liver tissue from control mice whereas minimal damage was noted in samples from HMGB 1 treated mice. [0074] To determine levels of inflammatory cytokines, serum levels of cytokines TNF and IL-6 were measured after I/R using ELISA kits from Biosource International (Camarillo, CA). Compared to sham-treated animals, liver I/R in control animals resulted in increased levels of TNF and IL-6 six hours after reperfusion (data not shown). However, animals pretreated with HMGBl exhibited lower levels of serum TNF and IL-6 compared to control animals subjected to I/R (Figure IB). [0075] To measure activation of NF-κB, a transcription factor involved in signal transduction of a variety of extracellular stress stimuli such as proinflammatory and protective responses in the liver, nuclear extracts were prepared from the ischemic livers and subjected to electrophoretic mobility shift assay (EMSA) as described in Tsung, et al., J. Exp, Med. 201: 1135-43 (2005). NF-κB DNA binding increased in the ischemic liver one hour after reperfusion in control mice when compared to sham-treated animals (Figure 1C). Mice pretreated with HMGBl exhibited less NF-κB DNA binding activity. The specificity of the NF-κB bands were confirmed by cold competition in the presence of excess unlabeled NF-κB consensus motif.
[0076] IRAK-M protein expression was upregulated in the livers in both control mice and in pretreated mice. Western blot analysis for IRAK-M and phosphorylated IRAK-I was performed for hepatic protein lysates of the ischemic lobes at the time points shown (Figure 2A). Mice pretreated with HMGBl exhibited higher hepatic IRAK-M levels after reperfusion than control mice (Figures 2 A-B). In contrast, control mice exhibited increased levels of phosphorylated IRAK-I after reperfusion . In mice pretreated with HMGBl, phosphorylated IRAK-I levels were lower than in control mice. Based on these results, lower IRAK-I phosphorylation in the livers of mice pretreated with HMGBl was associated with increased hepatic IRAK-M expression in the pretreated mice after I/R.
EXAMPLE 2
[0077] This example demonstrates that pretreatment with HMGB 1 can protect against I/R injury relating to TLR4 signaling.
[0078] TLR4-mutant (C3H/HeJ) mice and wild-type control (C3H/HeOuj) mice were subjected to liver I/R with or without HMGBl pretreatment as described in Example 1. Serum ALT levels, serum TNF and IL-ό levels, and hepatic IRAK-M expression were measured.
[0079] Based on serum ALT levels, control TLR4-mutant mice were protected from hepatic I/R injury compared to control wild-type mice. (Figure 3A). The protective effect of HMGBl pretreatment as seen in wild-type mice was not increased in TLR-4 mutant mice; TLR4~mutant mice were protected at the same level regardless of whether they received HMGBl pretreatment. Although the liver damage in TLR-4 mutant mice is approximately 50% less than in control wild-type mice, it is still much greater than sham animals. [0080] TLR4 wild-type mice treated with HMGBl exhibited decreased circulating TNF and IL-6 levels compared to control I/R animals, but TLR4-mutant mice treated with HMGBl showed no difference in levels of these cytokines when compared to mutant mice not receiving HMGBl (Figure 3B).
[0081] When hepatic IRAK-M was measured under conditions as described in Example 1, wild-type mice pretreated with HMGBl had higher expression of hepatic IRAK-M compared to wild- type control mice (Figure 4). However, there was no significant difference in IRAK-M expression between TLR4-mutant animals treated with or without HMGB 1.
EXAMPLE 3
(0082] This example demonstrates that pretreatment with lipopoly saccharides (LPS) does not protect against I/R injury to liver tissue.
[0083] Preconditioning during I/R can be triggered by diverse stimuli, including endotoxemia. To exclude a role for LPS in the protective effects seen with HMGBl pretreatment, mice were treated with varying doses of LPS and subjected to liver I/R. LPS from E. coli 0111 :B4 was obtained from Sigma (St. Louis, MO). Unlike mice pretreated with HMGBl, the mice pretreated with either 5 ng or 5 μg of LPS did not exhibit a reduction in I/R-induced damage compared to control animals (Figure 5). These results provide evidence against a contribution of contaminating LPS in the protection seen with HMGBl preconditioning.
EXAMPLE 4
[0084] This example demonstrates the use of HMGB 1 in treating myocardial infarction. [0085] A patient who has suffered myocardial infarction is administered 15 mg HMGB 1 intravenously within 30 minutes after infarction. Conventional treatments for myocardial infarction are also administered, including surgical repair, drug therapy, and/or insertion of a stent.
[0086] A patient who is being prepared for a surgical procedure bearing a risk of myocardial infarction is administered 15 mg HMGB 1 intravenously one hour prior to surgery. If myocardial infarction occurs during surgery, conventional treatments are administered. [0087] The injury to the treated patients' hearts due to myocardial infarction is decreased compared to the injury to the heart of a control patient treated only with conventional treatments.
EXAMPLE 5
[0088] This example demonstrates the use of HMGB 1 in treating ischemic stroke.
[0089] A patient who has suffered an ischemic stroke is administered 15 mg HMGB 1 intravenously within 30 minutes after the stroke. Conventional treatments for ischemic stroke are also administered.
[0090] A patient who is being prepared for a surgical procedure bearing a risk of stroke is administered 15 mg HMGBl intravenously one hour prior to surgery. If stroke occurs during surgery, conventional treatments are administered,
[0091] The injury to treated patients' brains due to stroke is decreased compared to the brain injury of a control patient treated only with conventional treatments.
EXAMPLE 6
[0092] This example demonstrates the use of HMGB 1 in treating traumatic injury. [0093] A patient who has suffered a traumatic injury is administered 15 mg of HMGB 1 intravenously within 30 minutes after injury. Conventional treatments for the traumatic injury are also administered,
[0094] The patient's injury is decreased compared to a control patient treated only with conventional treatments.
EXAMPLE 7
[0095] This example demonstrates the use of HMGBl in treating hemorrhagic shock. [0096J A patient who is suffering from hemorrhagic shock is administered 15 mg HMGBl intravenously within 30 minutes after the insult leading to shock occurs. Conventional treatments for hemorrhagic shock are also administered. [0097] A patient who is being prepared for a surgical procedure bearing a risk of extreme blood loss and/or hemorrhagic shock is administered 15 mg HMGB 1 intravenously one hour prior to surgery. If hemorrhagic shock occurs during surgery, conventional treatments are administered. [0098] The patient's injury is decreased compared to a control patient treated only with conventional treatments.
[0099] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[00100] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on. the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[00101] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments can become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

WE CLAIM:
1. A method of protecting an organ or tissue from ischemic injury comprising administering administration of a High Mobility Group Box 1 (HMGBl) protein to the organ or tissue, wherein the HMGBl protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
2. A method of protecting an organ or tissue from injury resulting from ischemia and reperfusion comprising administration of an HMGBl protein to the organ or tissue prior to completion of reperfusion, wherein the HMGBl protein is administered in an amount effective to protect the organ or tissue from injury.
3. The method of claim 2 wherein the ischemia and reperfusion is controlled.
4. The method of claim 2 wherein the ischemia and reperfusion is uncontrolled.
5. A method of protecting an organ or tissue from traumatic injury comprising administration of an HMGBl protein to the organ or tissue, wherein the HMGBl protein is administered in an amount effective to protect the organ or tissue from injury, and wherein the HMGBl protein is administered within a time period sufficient to protect the organ or tissue from injury.
6. The method of any of claims 1-5, comprising administration of an HMGBl protein.
7. The method of claim 6, wherein the HMGBl protein comprises a polypeptide having an amino acid sequence at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: I5 SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:24, and SEQ ID NOS: 27-38.
8. The method of claim 7, wherein the HMGB 1 protein comprises a polypeptide having the amino acid sequence of SEQ ID NO:2.
9. The method of claim 1, wherein the HMGB 1 protein consists of a polypeptide having the amino acid sequence of SEQ ID NO:2.
10. The method of any of claims 1-5, comprising administration of a biologically active fragment of an HMGBl protein.
11. The method of claim 105 wherein the biologically active fragment has an amino acid sequence at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO;55 SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NOS:20-23, and SEQ ID NOS:25-26.
12. The method of claim 10, wherein the biologically active fragment comprises a polypeptide having the amino acid sequence of SEQ ID NO:2ό.
13. The method of claim 10, wherein the biologically active fragment consists of a polypeptide having the amino acid sequence of SEQ ID NO:26.
14. The method of any of claims 1-5, wherein the HMGBl protein is administered prior to one hour after injury.
15. The method of claim 14, wherein the HMGBl protein is administered prior to 45 minutes after injury.
16. The method of claim 14, wherein the HMGBl protein is administered prior to 30 minutes after injury.
17. The method of claim 14, wherein the HMGBl protein is administered prior to 15 minutes after injury.
18. The method of claim 14, wherein the HMGBl protein is administered prior to 10 minutes after injury.
19. The method of claim 14, wherein the HMGBl protein is administered prior to 5 minutes after injury.
20. The method of claim 3, wherein the HMGBl protein is administered prior to the injury.
21. The method of claim 20, wherein the HMGB 1 protein is administered about one hour prior to the injury.
22. The method of claim 20, wherein the HMGBl protein is administered about 45 minutes prior to the injury.
23. The method of claim 20, wherein the HMGBl protein is administered about 30 minutes prior to the injury.
24. The method of claim 20, wherein the HMGBl protein is administered about 15 minutes prior to the injury.
25. The method of claim 20, wherein the HMGB 1 protein is administered about 10 minutes prior to the injury.
26. The method of claim 20, wherein the HMGBl protein is administered about 5 minutes prior to the injury.
27. The method of any of claims 1-5, wherein the organ or tissue is in a host.
28. The method of any of claims 1-5, wherein the organ or tissue is in vitro.
29. The method of claim 27, wherein the host is a human.
30. The method of claim 27, wherein the host is a non-human mammal.
31. The method of claim 27, wherein the HMGBl protein is administered systemically to the host.
32. The method of claim 27, wherein the HMGBl protein is administered by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, topical, transmucosal, or oral,
33. The method of any of claims 1-5, wherein the HMGBl protein is administered locally to the organ or tissue.
34. The method of any of claims 1 -5, wherein the HMGB 1 protein is administered in a dosage of about 5 μg to about 35 mg.
35. The method of claim 34, wherein the HMGBl protein is administered in a dosage of about 5 μg to about 20 μg.
36. The method of claim 34, wherein the HMGBl protein is administered in a dosage of about 20 μg to about 1 mg.
37. The method of claim 34, wherein the HMGBl protein is administered in a dosage of about 1 mg to about 10 mg.
38. The method of claim 34, wherein the HMGB 1 protein is administered in a dosage of about 10 mg to about 35 mg.
39. The method of claim 2, wherein the ischemia and reperfusion occur during transplantation of the organ from a donor to a recipient.
40. The method of claim 39, wherein the HMGB 1 protein is administered to the donor prior to ischemia.
41. The method of claim 39, wherein the HMGB 1 protein is administered to the recipient prior to reperfusion,
42. The method of claim 2, wherein the ischemia and reperfusion occur during a surgical procedure.
43. The method of any one of the preceding claims, wherein the organ or tissue is selected from the group consisting of a brain, a heart, a liver, a portion of a liver, a lung, a portion of a lung, a kidney, an intestine, a portion of an intestine, a pancreas, an eye, a muscle, a portion of a muscle, a bone, a portion of a bone, a nerve tissue, a vascular tissue, or an epithelial tissue.
44. The method of claim 43, wherein the organ or tissue is a heart.
45. The method of claim 43, wherein the organ or tissue is a brain.
46. The method of claim 43, wherein the organ or tissue is a liver or a portion of a liver.
47. The method of claim 43 , wherein the organ or tissue is a bone or a portion of a bone.
48. A method of preparing an organ or tissue for transplantation from a donor into a recipient comprising administration of an HMGBl protein to the donor, wherein the organ or tissue is within the donor.
49. The method of claim 48, wherein the donor is a cadaver donor.
50. The method of claim 48, wherein the donor is a human.
51. The method of claim 48, wherein the donor is a non-human mammal.
52. The method of claim 48, wherein the HMGBl protein is administered systemically to the donor.
53. The method of claim 48, wherein the HMGBl protein is administered locally to the organ.
54. The method of claim 48, wherein the HMGB 1 protein is administered by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, transmucosal, topical, or oral.
55. A method of preparing an organ or tissue for implantation into a recipient comprising administration of an HMGBl protein to the organ or tissue ex vivo.
56. The method of claim 55 wherein the recipient is a human.
57. The method of claim 55, wherein the recipient is a non-human mammal.
58. A composition for the prevention of injury to an organ following ischemia and reperfusion, comprising an HMGB 1 protein and a pharmaceutically acceptable carrier.
59. The composition of claim 58, wherein the composition is formulated for administration by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, transmucosal, topical, or oral.
60. The composition of claim 58, further comprising one or more components selected from the group consisting of diluents, adjuvants, excipients, or pH adjusting agents.
61. A kit comprising a composition for the prevention of injury to an organ following ischemia and reperfusion and suitable instructions for administration, and optionally comprising a means for administration of the composition, wherein the composition comprises an HMGB 1 protein and a pharmaceutically acceptable carrier.
62. Use of an HMGB 1 protein in preparation of a medicament for use in protecting an organ from injury caused by an event selected from the group consisting of ischemia, reperfusion, and trauma.
63. The use of claim 62, wherein the organ or tissue is selected from the group consisting of a brain, a heart, a liver, a portion of a liver, a lung, a portion of a lung, a kidney, an intestine, a portion of an intestine, a pancreas, an eye, a muscle, a portion of a muscle, a bone, a portion of a bone, a nerve tissue, a vascular tissue, or an epithelial tissue.
64. The method of claim 63, wherein the organ or tissue is a heart.
65. The method of claim 63 , wherein the organ or tissue is a brain.
66. The method of claim 63, wherein the organ or tissue is a liver or a portion of a liver. 61, The method of claim 63, wherein the organ or tissue is a bone or a portion of a bone.
68. The use of claim 62, wherein the medicament is formulated for administration by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, transmucosal, topical, or oral.
69. The method of claim 1, comprising administration of an HMGB 1 protein.
70. The method of claim 69, wherein the HMGB 1 protein comprises a polypeptide having an amino acid sequence at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:24, and SEQ ID NOS: 27-38.
71. The method of claim 70, wherein the HMGB 1 protein comprises a polypeptide having the amino acid sequence of SEQ ID NO:2.
72. The method of claim 70, wherein the HMGB 1 protein consists of a polypeptide having the amino acid sequence of SEQ ID NO:2.
73. The method of claim 1, comprising administration of a biologically active fragment of an HMGB 1 protein.
74. The method of claim 73, wherein the biologically active fragment has an amino acid sequence at least 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:4S SEQ ID NO:5, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NOS:20-23, and SEQ ID NOS:25-26.
75. The method of claim 73, wherein the biologically active fragment comprises a polypeptide having the amino acid sequence of SEQ ID NO:26.
76. The method of claim 73, wherein the biologically active fragment consists of a polypeptide having the amino acid sequence of SEQ ID NO:26.
77. The method of claim 1 , wherein the HMGB 1 protein is administered prior to one hour after injury.
78. The method of claim 77, wherein the HMGB 1 protein is administered prior to 45 minutes after injury.
79. The method of claim 77, wherein the HMGB 1 protein is administered prior to 30 minutes after injury.
80. The method of claim 77, wherein the HMGB 1 protein is administered prior to 15 minutes after injury.
81. The method of claim 77, wherein the HMGB 1 protein is administered prior to 10 minutes after injury,
82. The method of claim 77, wherein the HMGB 1 protein is administered prior to 5 minutes after injury.
83. The method of claim 3, wherein the HMGBl protein is administered prior to the injury.
84. The method of claim 83, wherein the HMGB 1 protein is administered about one hour prior to the injury.
85. The method of claim 83, wherein the HMGBl protein is administered about 45 minutes prior to the injury.
86. The method of claim 83, wherein the HMGBl protein is administered about 30 minutes prior to the injury.
87. The method of claim 83, wherein the HMGBl protein is administered about 15 minutes prior to the injury.
88. The method of claim 83, wherein the HMGBl protein is administered about 10 minutes prior to the injury.
89. The method of claim 83, wherein the HMGBl protein is administered about 5 minutes prior to the injury.
90. The method of claim 1, wherein the organ or tissue is in a host.
91. The method of claim 1 , wherein the organ or tissue is in vitro.
92. The method of claim 90, wherein the host is a human.
93. The method of claim 90, wherein the host is a non-human mammal.
94. The method of claim 90, wherein the HMGBl protein is administered systemicaily to the host.
95. The method of claim 90, wherein the HMGB 1 protein is administered by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, topical, transmucosal, or oral.
96. The method of claim 1 , wherein the HMGB 1 protein is administered locally to the organ or tissue.
97. The method of claim 1 , wherein the HMGB 1 protein is administered in a dosage of about 5 μg to about 35 mg.
98. The method of claim 97, wherein the HMGB 1 protein is administered in a dosage of about 5 μg to about 20 μg.
99. The method of claim 97, wherein the HMGBl protein is administered in a dosage of about 20 μg to about 1 mg.
100. The method of claim 97, wherein the HMGBl protein is administered in a dosage of about 1 mg to about 10 mg.
101. The method of claim 97, wherein the HMGB 1 protein is administered in a dosage of about 10 mg to about 35 mg.
102. The method of claim 2, wherein the ischemia and reperfusion occur during transplantation of the organ from a donor to a recipient.
103. The method of claim 102, wherein the HMGB 1 protein is administered to the donor prior to ischemia.
104. The method of claim 102, wherein the HMGB 1 protein is administered to the recipient prior to reperfusion.
105. The method of claim 2, wherein the ischemia and reperfusion occur during a surgical procedure.
106. The method of claim 1 , wherein the organ or tissue is selected from the group consisting of a brain, a heart, a liver, a portion of a liver, a lung, a portion of a lung, a kidney, an intestine, a portion of an intestine, a pancreas, an eye, a muscle, a portion of a muscle, a bone, a portion of a bone, a nerve tissue, a vascular tissue, or an epithelial tissue.
107. The method of claim 106, wherein the organ or tissue is a heart.
108. The method of claim 106, wherein the organ or tissue is a brain.
109. The method of claim 106, wherein the organ or tissue is a liver or a portion of a liver.
110. The method of claim 106, wherein the organ or tissue is a bone or a portion of a bone.
11 1. A method of preparing an organ or tissue for transplantation from a donor into a recipient comprising administration of an HMGB 1 protein to the donor, wherein the organ or tissue is within the donor.
112. The method of claim 111, wherein the donor is a cadaver donor.
113. The method of claim 111, wherein the donor is a human.
114. The method of claim 111 > wherein the donor is a non-human mammal.
115. The method of claim 111, wherein the HMGB 1 protein is administered systemically to the donor.
116. The method of claim 111, wherein the HMGB 1 protein is administered locally to the organ.
117. The method of claim 111, wherein the HMGB 1 protein is administered by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, transmucosal, topical, or oral.
118. A method of preparing an organ or tissue for implantation into a recipient comprising administration of an HMGB 1 protein to the organ or tissue ex vivo.
1 19. The method of claim 118 wherein the recipient is a human.
120. The method of claim 118, wherein the recipient is a non-human mammal.
121. A composition for the prevention of injury to an organ following ischemia and reperfusion, comprising an HMGBl protein and a pharmaceutically acceptable carrier.
122. The composition of claim 118, wherein the composition is formulated for administration by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, transmucosal, topical, or oral.
123. The composition of claim 118, further comprising one or more components selected from the group consisting of diluents, adjuvants, excipients, or pH adjusting agents.
124. A kit comprising a composition for the prevention of injury to an organ following ischemia and reperfusion and suitable instructions for administration, and optionally comprising a means for administration of the composition, wherein the composition comprises an HMGB 1 protein and a pharmaceutically acceptable carrier.
125. Use of an HMGB 1 protein in preparation of a medicament for use in protecting an organ from injury caused by an event selected from the group consisting of ischemia, reperfusion, and trauma.
126. The use of claim 125, wherein the organ or tissue is selected from the group consisting of a brain, a heart, a liver, a portion of a liver, a lung, a portion of a lung, a kidney, an intestine, a portion of an intestine, a pancreas, an eye, a muscle, a portion of a muscle, a bone, a portion of a bone, a nerve tissue, a vascular tissue, or an epithelial tissue.
127. The method of claim 126, wherein the organ or tissue is a heart.
128. The method of claim 126, wherein the organ or tissue is a brain.
129. The method of claim 126, wherein the organ or tissue is a liver or a portion of a liver.
130. The method of claim 126, wherein the organ or tissue is a bone or a portion of a bone.
131. The use of claim 125, wherein the medicament is formulated for administration by a route selected from the group consisting of intravenous, intramuscular, intraperitoneal, percutaneous, subcutaneous, transmucosal, topical, or oral.
PCT/US2007/061709 2006-02-06 2007-02-06 Use of hmgb1 for protection against ischemia reperfusion injury WO2007130725A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76554506P 2006-02-06 2006-02-06
US60/765,545 2006-02-06

Publications (2)

Publication Number Publication Date
WO2007130725A2 true WO2007130725A2 (en) 2007-11-15
WO2007130725A3 WO2007130725A3 (en) 2008-04-10

Family

ID=38668413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/061709 WO2007130725A2 (en) 2006-02-06 2007-02-06 Use of hmgb1 for protection against ischemia reperfusion injury

Country Status (2)

Country Link
US (1) US7829097B2 (en)
WO (1) WO2007130725A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884076A (en) * 2012-10-25 2015-09-02 吉诺米克斯股份有限公司 Novel method for treating cardiac infarction using hmgb1 fragment
AU2012248676B2 (en) * 2011-04-26 2017-04-20 Osaka University Peptide for inducing regeneration of tissue and use thereof
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
US9919010B2 (en) 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE547048T1 (en) 2003-08-12 2012-03-15 Univ Loma Linda Med MODULAR PATIENT SUPPORT SYSTEM
CN101374538A (en) * 2006-10-30 2009-02-25 吉诺米克斯股份有限公司 Pharmaceutical for promoting functional regeneration of damaged tissue
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
NZ702839A (en) 2010-06-09 2016-04-29 Univ Arkansas Vaccine and methods to reduce campylobacter infection
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
PT2956165T (en) 2013-02-14 2019-11-29 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
JP7467027B2 (en) 2016-05-03 2024-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Yeast vaccine vectors containing immunostimulatory and antigenic polypeptides and methods of using same
CA3051825A1 (en) * 2017-01-27 2018-08-02 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
WO2018199107A1 (en) * 2017-04-25 2018-11-01 塩野義製薬株式会社 Peptide for inducing regeneration of tissue, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026691A2 (en) * 2001-09-25 2003-04-03 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for the activation of dendritic cells
WO2004004763A2 (en) * 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004061456A2 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2447576C (en) 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026691A2 (en) * 2001-09-25 2003-04-03 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for the activation of dendritic cells
WO2004004763A2 (en) * 2002-07-03 2004-01-15 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004061456A2 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9919010B2 (en) 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
US11197895B2 (en) 2008-04-30 2021-12-14 StemRIM Inc. Method for collecting functional cells in vivo with high efficiency
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
AU2012248676B2 (en) * 2011-04-26 2017-04-20 Osaka University Peptide for inducing regeneration of tissue and use thereof
EP2703487B1 (en) * 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
AU2019210647B2 (en) * 2011-04-26 2021-12-23 Osaka University Peptide for inducing regeneration of tissue and use thereof
US10550165B2 (en) 2011-04-26 2020-02-04 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
US10364276B2 (en) 2011-04-26 2019-07-30 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
EP3358011A1 (en) * 2011-04-26 2018-08-08 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
RU2647467C2 (en) * 2012-10-25 2018-03-15 Дженомикс Ко., Лтд. New method of treatment of myocardial infarction with application of fragment hmgb1
EP2913058A4 (en) * 2012-10-25 2016-04-13 Genomix Co Ltd Novel method for treating cardiac infarction using hmgb1 fragment
US9623078B2 (en) 2012-10-25 2017-04-18 Genomix Co., Ltd. Method for treating cardiac infarction using HMGB1 fragment
AU2013335684B2 (en) * 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
KR102146815B1 (en) 2012-10-25 2020-08-21 가부시키가이샤 스템림 Novel method for treating cardiac infarction using HMGB1 fragment
KR20150103660A (en) * 2012-10-25 2015-09-11 가부시키가이샤 제노믹스 Novel method for treating cardiac infarction using HMGB1 fragment
EP2913058A1 (en) * 2012-10-25 2015-09-02 Genomix Co., Ltd. Novel method for treating cardiac infarction using hmgb1 fragment
CN104884076A (en) * 2012-10-25 2015-09-02 吉诺米克斯股份有限公司 Novel method for treating cardiac infarction using hmgb1 fragment
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease

Also Published As

Publication number Publication date
US7829097B2 (en) 2010-11-09
US20080004207A1 (en) 2008-01-03
WO2007130725A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
US7829097B2 (en) Use of HMGB1 for protection against ischemia reperfusion injury
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
EP2349310B1 (en) Polypeptide for treating or preventing adhesions
JP2009523818A (en) Protection method from ischemic disease
JP2009522209A (en) Sustained release of neuregulin to improve cardiac function
CN111432829A (en) Peptides for treating and preventing non-alcoholic fatty liver disease and fibrosis
KR20190075968A (en) New PEGylated liposomal preparations of apelin for the treatment of cardiovascular-related disorders
KR20140032955A (en) Inhibitors of apoptosis and uses thereof
WO2013059879A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
US20090275503A1 (en) Diastereomeric peptides for modulating t cell immunity
CA2539440A1 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
EP2717894B1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
CA2072253A1 (en) Anti-inflammatory peptides and treatment to inhibit vascular leakage in injured tissues
KR101933543B1 (en) Use of a neuregulin to treat peripheral nerve injury
EP0983300B1 (en) Bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
AU2006301494A1 (en) Antagonists against interaction of PF4 and RANTES
WO2012030949A2 (en) B2-glycoprotein i peptide inhibitors
JP6302936B2 (en) Methods and pharmaceutical compositions for cardioprotection
JPWO2002072131A1 (en) Liver disease drug
KR20160127017A (en) Attenuation of intrapulmonary inflammation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797125

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07797125

Country of ref document: EP

Kind code of ref document: A2